EGFR and adenocarcinoma: The HR for 1‐year OS for erlotinib recipients was 1.10 (1.03–1.18) in the whole cohort, 1.08 (0.98–1.18) in the EGFR‐TKI responders, 1.08 (1.02–1.16) in the adherent subgroup, 1.89 (1.62–2.09) in the adenocarcinoma subgroup, and 1.87 (1.47–2.37) in the adenocarcinoma with second‐line TKIs subgroup (Table 4).